Convalescent plasma and <scp>COVID</scp> ‐19: Time for a second—second look?-Reference-Cited by-同舟云学术

Convalescent plasma and COVID ‐19: Time for a second—second look?

Published:2022-09-11 Issue:1 Volume:33 Page:16-20
ISSN:0958-7578
Container-title:Transfusion Medicine
language:en
Short-container-title:Transfusion Medicine

Author:

Joyner Michael J.¹,Carter Rickey E.²,Fairweather DeLisa³,Wright R. Scott⁴

Affiliation:

1. Department of Anesthesiology & Perioperative Medicine Mayo Clinic Rochester Minnesota USA

2. Department of Quantitative Health Sciences, Division of Clinical Trials & Biostatistics Mayo Clinic Jacksonville Florida USA

3. Department of Cardiovascular Diseases Mayo Clinic Jacksonville Florida USA

4. Department of Cardiovascular Diseases Mayo Clinic Rochester Minnesota USA

Funder

Biomedical Advanced Research and Development Authority

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tme.12915

Reference30 articles.

1. Convalescent plasma use in the USA was inversely correlated with COVID‐19 mortality;Casadevall A;Elife,2021

2. Administration FUSFD. (2020).Coronavirus (COVID‐19) Update: FDA Coordinates National Effort to Develop Blood‐Related Therapies for COVID‐19.

3. Real-World Evidence — Where Are We Now?

4. JoynerMJ CasadevallA.For early testing of convalescent plasma we were ‘building the plane while we were flying it’. In. Stat News: First Opinion 2021.

5. Administration FUSFD.Expanded Access: Information about Expanded Access. FDA U. S Food & Drug Administrationhttps://www.fda.gov/news-events/public-health-focus/expanded-access

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 Convalescent Plasma Therapy in Korea;The Korean Journal of Blood Transfusion;2024-04-30

2. Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID‐19: An early phase 1 descriptive study;Health Science Reports;2024-03

3. Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review;Life;2024-02-01

4. Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS‐CoV‐2 Variants: A Case Report Study with Comparison to a Vaccinated Population;Case Reports in Infectious Diseases;2024-01

5. Evidence for the Efficacy of COVID-19 Convalescent Plasma;Current Topics in Microbiology and Immunology;2024